Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | Talquetamab, cevostamab and CAR-T in the future treatment of myeloma

Luciano Costa • 6 Sep 2021
IMW 2021
Multiple Myeloma Antibodies CAR-T Cevostamab Ciltacabtagene autoleucel Idecabtagene vicleucel Talquetamab

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, Birmingham, AL, outlines how the latest drug therapies can be integrated into the treatment algorithm for multiple myeloma. Dr Costa also explains the excitement surrounding chimeric antigen receptor (CAR) T-cell therapies, such as idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), and bispecific antibodies, such as talquetamab and cevostamab, for the treatment of myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

More from Luciano Costa

1:45
Challenges for community clinicians treating multiple myeloma
Luciano Costa • 11 Dec 2023
2:02
Alnuctamab, a BCMA x CD3 TCE, in the treatment of multiple myeloma
Luciano Costa • 11 Dec 2023
2:40
Dual-targeting of Slamf-7 and CD38 with elotuzumab and isatuximab in multiple myeloma
Luciano Costa • 11 Dec 2023
3:38
Outcomes for patients with multiple myeloma who have had first-line monoclonal antibody exposure
Luciano Costa • 11 Dec 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals